secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2026-07-30T20:03:20+00:00
Accession:  0001104659-26-088662
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Yarrow Bioscience exchanges shares for pre-funded warrants; warrant count dwarfs common shares
--------------------------------------------------------------------------------

- Exchanged 133,290 common shares for pre-funded warrants to purchase same number at $0.0001/share.
- After exchange: 2,669,788 common shares outstanding; 25,914,530 pre-funded warrants outstanding.
- Warrants immediately exercisable, subject to 9.99% beneficial ownership limitation (can be increased to 19.99%).
- Exchange closed July 29, 2026; issued under Section 3(a)(9) exemption from registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/0001104659-26-088662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/tm2621655d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer